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Background: Recent genome-wide studies have shown that approximately 30% of diffuse large B-cell lymphoma
(DLBCL) cases harbor mutations in the histone acetyltransferase (HAT) coactivators p300 or CBP. The majority of
these mutations reduce or eliminate the catalytic HAT activity. We previously demonstrated that the human DLBCL
cell line RC-K8 expresses a C-terminally truncated, HAT-defective p300 protein (p300ΔC-1087), whose expression is
essential for cell proliferation.
Methods: Using results from large-scale DLBCL studies, we have identified and characterized a second C-terminally
truncated, HAT-defective p300 mutant, p300ΔC-820, expressed in the SUDHL2 DLBCL cell line. Properties of
p300ΔC-820 were characterized in the SUDHL2 DLBCL cell line by Western blotting, co-immunoprecipitation, and
shRNA gene knockdown, as well by using cDNA expression vectors for p300ΔC-820 in pull-down assays, transcriptional
reporter assays, and immunofluorescence experiments. A mass spectrometry-based method was used to compare
the histone acetylation profile of DLBCL cell lines expressing various levels of wild-type p300.
Results: We show that the SUDHL2 cell line expresses a C-terminally truncated, HAT-defective form of p300
(p300ΔC-820), but no wild-type p300. The p300ΔC-820 protein has a wild-type ability to localize to subnuclear
“speckles,” but has a reduced ability to enhance transactivation by transcription factor REL. Knockdown of
p300ΔC-820 in SUDHL2 cells reduced their proliferation and soft agar colony-forming ability. In RC-K8 cells, knockdown
of p300ΔC-1087 resulted in increased expression of mRNA and protein for REL target genes A20 and IκBα, two genes
that have been shown to limit the growth of RC-K8 cells when overexpressed. Among a panel of B-lymphoma cell
lines, low-level expression of full-length p300 protein, which is characteristic of the SUDHL2 and RC-K8 cells, was
associated with decreased acetylation of histone H3 at lysines 14 and 18.
Conclusions: The high prevalence of p300 mutations in DLBCL suggests that HAT-deficient p300 activity defines
a subtype of DLBCL, which we have investigated using human DLBCL cell lines RC-K8 and SUDHL2. Our results
suggest that truncated p300 proteins contribute to DLBCL cell growth by affecting the expression of specific
genes, perhaps through a mechanism that involves alterations in global histone acetylation.
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Diffuse large B-cell lymphoma (DLBCL) accounts for
approximately 30% of B-cell lymphoma cases [1]. Mo-
lecular profiling of DLBCL cell lines and patient tumors
has led to the identification of distinct subtypes, which
has been a useful tool in predicting patient survival and
therapeutic response [2]. Genome-wide studies have
shown that approximately 30% of DLBCL tumors harbor
mutations in two highly related histone acetyltransferase
(HAT) genes, EP300 and CREBBP [3-7].
EP300 and CREBBP encode related HATs, p300 and
CBP, respectively, that have widespread genomic effects
on chromatin structure and gene expression as well as
non-genomic effects on protein function [8]. These HATs
serve as coactivators for many transcription factors, either
through acetylation of lysine residues on histones to
modify DNA structure at sites of active transcription or
through acetylation of transcription factors to modify
their activity. In both cases, the centrally-located, catalytic
HAT domain is required for these effects on transcription.
Consistent with its broad role in transcriptional control,
p300 can directly interact with a wide variety of transcrip-
tion factors, including NF-κB [9,10], p53 [11,12], MyoD
[13], HIF-1α [14], BRCA1 [15], and Ets-1 [16]. In addition,
p300 and CBP contain several protein-protein interaction
domains and can exhibit HAT-independent functions;
for example, p300 can enhance transcription simply by
recruiting proteins to transcriptional start sites, including
members of the transcription pre-initiation complex and
the RNA polymerase holo-enzyme [8,17].
Most p300/CBP mutations identified in DLBCL are
point mutations, nonsense mutations, or deletions that
disable HAT activity [3,5,10,18]. In some epithelial cancers
where a truncated p300/CBP protein is expressed, the
wild-type allele is silenced or otherwise inactivated [19],
and ectopic expression of wild-type p300 in some HAT-
deficient p300 cancer cell lines slows cell growth [7,20].
Such results have led p300 to be classified as a tumor sup-
pressor, arising from the hypothesis that it is the loss of
wild-type p300 activity which contributes to oncogenesis.
We have previously shown that, due to a 3’ alteration
in one copy of the EP300 gene, the DLBCL cell line
RC-K8 expresses a C-terminally truncated HAT-deficient
p300 protein (herein called p300ΔC-1087). Even though
the other copy of the EP300 locus appears intact, RC-K8
cells express low to undetectable levels of wild-type p300
mRNA and protein [10,18]. We previously reported that
the RC-K8 p300ΔC-1087 could not act as a coactivator
for the REL transcription factor [18]. Of note, knockdown
of p300ΔC-1087 expression reduces the proliferation and
soft agar colony-forming ability of RC-K8 cells [18], and
re-expression of wild-type p300 is tolerated in RC-K8
cells, but sensitizes them to the cell killing effects of
small-molecule BCL6 inhibitors [7]. Other studies havedemonstrated that expression of a HAT domain mutant
of p300 results in increased proliferation of hematopoietic
stem and progenitor cells, whereas complete loss of p300
does not [21]. Such findings suggest that p300 HAT
activity normally limits B-cell proliferation, and that ex-
pression of p300 proteins with an inactive catalytic domain
contributes to B-cell growth, survival, and tumorigenesis.
In this report, we have characterized a truncated p300
protein expressed in the DLBCL cell line SUDHL2.
We show that this C-terminally truncated and HAT-
deficient p300 mutant is a weak transcriptional coactivator,
and that its expression is required for the optimal growth
of SUDHL2 cells. These results and others suggest that
expression of C-terminally truncated p300 coactivators
defines a subset of DLBCL that utilize distinct onco-
genic pathways.Results
The SUDHL2 DLBCL cell line expresses a C-terminally
truncated p300 protein
Pasqualucci et al. [3] reported that several human DLBCL
cell lines, including BJAB, Farage, SUDHL2 and SUDHL8,
express no detectable full-length p300 protein. Because of
our ongoing interest in p300 mutations in DLBCL [10,18],
we sought to further characterize p300 status in these four
cell lines. In particular, the reported absence of full-length
p300 in BJAB and Farage cells is in contrast to our previ-
ous findings [10] and those of others [7,22-25]. Therefore,
we reassessed p300 expression in these four DLBCL cell
lines by Western blotting of whole-cell extracts, and
included multiple independent cell lines in our analyses
(including the ones used by Pasqualucci et al. [3]). As a
further control, we analyzed RC-K8 cells, which we have
previously shown express little or no full-length p300
[10,18]. As shown in Figure 1a, multiple isolates of BJAB,
Farage, and SUDHL8 cells express easily detectable levels
of full-length p300. In contrast, RC-K8 and SUDHL2 cells
do not express detectable levels of full-length p300.
Although full-length p300 is not expressed in RC-K8
cells, these cells do express a C-terminally truncated
p300 protein (p300ΔC-1087) [10,18]. Due to the absence
of full-length p300 in SUDHL2 cells (Figure 1a) and the
reported nonsense mutation at EP300 codon 821 in these
cells [3], we next determined whether SUDHL2 cells
express a C-terminally truncated form of p300. Western
blotting using an antibody against N-terminal sequences
of p300 showed that SUDHL2 cells express a smaller form
of p300 under conditions where there is no detectable
full-length p300 (Figure 1b). Consistent with the size
expected for the reported codon 821 nonsense mutation
[3], the single anti-p300-reactive protein in SUDHL2 cell
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Figure 1 Expression of p300 proteins in DLBCL cell lines.
(a) Anti-p300 Western blotting was performed on whole-cell extracts
from the indicated DLBCL cell lines. The sources of the cell lines are
described in Materials and methods and in the indicated references in
the figure. Thirty-five μg of total protein from whole-cell extracts was
loaded for all samples except for RC-K8 (50 μg). (b) SUDHL2 cells
express a C-terminally truncated p300 protein (p300ΔC-820).
Whole-cell extracts from the six indicated cell lines were analyzed
by Western blotting for relative expression of p300. The amount of
total cell protein loaded is indicated. Western blots were performed
with N-terminal anti-p300 antiserum. p300 expression was quantified
by densitometric analysis and is relative to full-length p300 in Ramos
cells (100). Relative p300 expression for the SUDHL2 and RC-K8 cell
lines was determined by analyzing the bands corresponding to
p300ΔC-820 and p300ΔC-1087, respectively. Full-length p300 in
SUDHL2 and RC-K8 cell lines was undetectable (0). (c) Whole-cell
extracts from the six indicated DLBCL cell lines were analyzed by
Western blotting for expression of CBP. Twenty-five μg of whole-cell
extract was used for each sample. Western blotting was performed
with anti-CBP and anti-β-tubulin (as a loading control) antisera.
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hemizygous for the EP300 gene and contain only the
codon 821 mutant allele. To confirm that SUDHL2 cellslack wild-type EP300 sequences, we PCR-amplified and
then sequenced EP300 genomic DNA flanking codon
821 in exon 14. Our results confirmed that the amplified
DNA only contained the C2856T mutation (CAG to TAG)
at codon 821 in exon 14 (Additional file 1), demonstrating
that there is no wild-type EP300 locus in SUDHL2 cells.
Quantitation of p300 levels indicated that the trun-
cated p300 proteins in RC-K8 and SUDHL2 cells are
expressed at low levels compared to full-length p300 in
four other B-lymphoma cell lines (Figure 1b, relative p300
values). In contrast, the levels of the related HAT CBP
were similar in all six cell lines, and certainly did not vary
depending on whether a given cell line expressed full-
length or truncated p300 (Figure 1c). These results
demonstrate that neither overexpression of mutant p300
nor compensatory changes in CBP expression occurs in
B-lymphoma cell lines expressing truncated p300 mutants.
Instead, the expression of a truncated p300 appears to be
associated with reduced expression of full-length p300.
Characterization of the p300ΔC-820 protein from
SUDHL2 cells
To further characterize the p300ΔC-820 protein, we
created a CMV promoter-based plasmid expression vector
for p300ΔC-820 by mutating codon 821 to a stop codon
in a full-length p300 cDNA, based on the nonsense muta-
tion in SUDHL2 genomic DNA. When transfected into
A293T cells, the synthetic p300ΔC-820 cDNA directed
the expression of a protein that nearly co-migrated with
p300ΔC-820 from SUDHL2 cells (Figure 2a).
We next analyzed the subcellular localization of ectopi-
cally expressed p300ΔC-820 in transfected fibroblasts.
As shown in Figure 2b, overexpressed wild-type p300,
p300ΔC-1087, and p300ΔC-820 predominantly localized
to discrete punctate regions of the nucleus (“speckles”)
in transfected fibroblasts. This speckled localization of
p300ΔC-820 is similar to the staining seen with wild-
type p300 and p300ΔC-1087 (from RC-K8 cells), but is
distinct from the overall nuclear DNA staining seen
with DAPI.
We have previously shown that wild-type p300 can
enhance the ability of transcription factor REL to activate
a multimeric κB-site reporter gene, whereas p300ΔC-1087
cannot [18]. In more extensive studies, we now find that
high amounts of p300ΔC-820 and p300ΔC-1087 can
weakly enhance transactivation by REL. Consistent with
previous results [18], wild-type p300 enhanced the ability
of REL to activate the κB-site reporter in A293 cells by
approximately 2.5-fold (Figure 2c). In contrast, p300ΔC-
820 and p300ΔC-1087 enhanced REL-dependent transac-
tivation, on average, by only 1.6- and 1.4-fold, respec-
tively (Figure 2c). To further assess the ability of these
C-terminally truncated mutants to enhance REL-dependent
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Figure 2 p300ΔC-820 localizes to the nucleus, but only weakly enhances REL transactivation. (a) Anti-p300 Western blotting was performed
on extracts from control A293T cells, p300ΔC-820-transfected A293T cells, and SUDHL2 cells. Twenty-five μg of control A293T and SUDHL2 total protein
and 30 ng of p300ΔC-820-transfected A293T total protein were loaded. p300ΔC-820-transfected A293T and SUDHL2 extracts were loaded together in
the last lane. (b) DF-1 chicken fibroblasts were transfected with 3 μg of pCMVβ-p300, pCMVβ- p300ΔC-1087, or pCMVβ- p300ΔC-820 as indicated.
Indirect immunofluorescence was performed using a primary anti-p300 antiserum and a FITC-conjugated anti-rabbit secondary antibody (top row).
Nuclei were visualized by DAPI staining (bottom row). (c) A293 cells were co-transfected with 0.5 μg of pcDNA-REL along with 0.5 μg of
pCMVβ-p300, pCMVβ-p300ΔC-1087, or pCMVβ-p300ΔC-820 as indicated. Western blotting shows relative p300 and REL expression in
transfected cells (bottom panel). Luciferase and β-galactosidase activities were determined, and values were normalized to control transfections
(1.0, top panel). Error bars represent standard error of the mean. Asterisks represent p-value < 0.05 for the difference between the indicated value and
the control value (1.0) in a one-tailed t-test. (d) A293 cells were co-transfected with 0.5 μg of pcDNA-REL and the indicated amounts of pCMVβ-p300,
pCMVβ-p300ΔC-820, or pCMVβ-p300ΔC-1087. Luciferase and β-galactosidase activities were determined, and values were normalized to REL-alone
control transfections as indicated (1.0, white bar). Total DNA within each experiment was kept constant by the addition of empty pcDNA3.1 vector. For
all reporter assays, values are the averages of at least three experiments, each performed with duplicate or triplicate samples. Error bars represent
standard error of the mean.
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820 or p300ΔC-1087 expression plasmids and measured
transcriptional activation of the κB-site reporter. Like
wild-type p300, both p300ΔC-820 and p300ΔC-1087
enhanced REL-dependent transactivation in a generally
dose-dependent manner (Figure 2d). However, both p300
mutants enhanced transcription to a lesser extent than
an equimolar amount of wild-type p300 (e.g., 500 ng of
p300ΔC-820 plasmid enhanced REL-dependent transacti-
vation by 1.5-fold, whereas 500 ng of wild-type p300 plas-
mid resulted in a 2.4-fold enhancement). Together, these
results demonstrate that both p300ΔC-820 and p300ΔC-
1087 can enter the nucleus and function as relatively weak
coactivators for REL-dependent transactivation.p300ΔC-820 interacts with REL transactivation domain
sequences in vitro and in vivo
We have previously shown that p300ΔC-1087 retains the
ability to interact with transcription factor REL in vitro and
in RC-K8 cells, and that this interaction primarily occurs
via the C-terminal transactivation domain (TAD) of REL
[10]. To determine whether p300ΔC-820 also has the
ability to interact with REL, a pull-down assay was per-
formed using a GST-REL-TAD fusion protein and whole-
cell extracts from SUDHL2 cells. Anti-p300 Western
blotting showed that GST-REL-TAD specifically pulled
down p300ΔC-820 (Figure 3a). As a control, GST-REL-
TAD was incubated with whole-cell extracts from A293

























































































































Figure 3 p300ΔC-820 interacts with REL in vitro and in vivo. (a) A GST-REL-TAD (aa 324-587) pulldown was performed on whole-cell extracts
from SUDHL2 (p300ΔC-820, top panel) or A293 cells (wild-type 300, middle panel). Bound proteins were subjected to anti-p300 Western blotting
to detect p300ΔC-820 or WT p300, as indicated. (b) GST-p300 pulldown of endogenous REL from SUDHL2 whole-cell extracts. Bound proteins
were subjected to anti-REL Western blotting. The structure of wild-type p300 is shown and structures of GST-p300 mutants used are indicated.
(c) Nuclear extracts of A293 cells co-transfected with p300ΔC-820 and REL were immunoprecipitated with normal rabbit IgG or anti-p300 antiserum.
Immunoprecipitates were subjected to anti-REL or anti-p300 Western blotting, as indicated. One percent (3 μg) of the nuclear extract used for
immunoprecipitation was included as an input for the anti-REL blot and 10% (30 μg) of the nuclear extract was used as input for the anti-p300 blot.
(d) Nuclear extracts of SUDHL2 cells were immunoprecipitation with normal rabbit IgG or anti-p300 antiserum. Immunoprecipitates were subjected to
anti-REL or anti-p300 Western blotting, as indicated. Ten percent (25 μg) of the nuclear extract used for immunoprecipitate was included as an input
for the anti-REL blot and 30% (75 μg) of the nuclear extract was used as input for the anti-p300 blot. Coomassie Blue staining was performed on 5% of
GST or GST-fusion protein used in the pulldowns (a, b lower panels).
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fusion protein containing the CH1 protein interaction
domain (aa 300-528, retained in p300ΔC-820) could pull-
down REL from SUDHL2 whole-cell extracts (Figure 3b).
This ability to pull-down REL was lost when a smaller
CH1 region was used (aa 340-528) (Figure 3b), indicating
that the entire CH1 domain of p300 is required for effi-
cient binding to REL.
To determine whether p300ΔC-820 retains the ability
to interact with REL in vivo, we performed an anti-p300
immunoprecipitation from A293 cells co-transfected with
expression plasmids for p300ΔC-820 and REL. Anti-REL
Western blotting of an anti-p300 immunoprecipitate
demonstrated that REL can interact with p300ΔC-820,at least when overexpressed in a non-lymphoid cell type
(Figure 3c). To determine whether endogenous p300ΔC-
820 and REL interact in SUDHL2 cells, we performed
an anti-p300 immunoprecipitation on nuclear extracts.
Anti-REL Western blotting of the anti-p300 immuno-
precipitate demonstrated that REL is also present, indicat-
ing that REL and p300ΔC-820 interact in SUDHL2 cells
(Figure 3d).
Knockdown of p300ΔC-820 reduces the growth of
SUDHL2 cells
To determine whether p300ΔC-820 contributes to the
growth of SUDHL2 cells (which contain no wild-type
EP300 allele), we first knocked down expression of
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taining a short hairpin RNA (shRNA) that has been pre-
viously shown to knock down expression of wild-type
p300 [26] and p300ΔC-1087 [18]. Western blotting showed
that p300ΔC-820 expression was reduced by approximately
67% in a pool of SUDHL2 cells expressing p300 shRNA
as compared to SUDHL2 cells expressing a control, non-
targeting shRNA (Figure 4a). We next compared the
proliferation of SUDHL2 cells expressing p300 shRNA
and control shRNA by counting cells over the course of
four days. Knockdown of p300ΔC-820 reduced the pro-
liferation of SUDHL2 in liquid medium (Figure 4b). In
addition, SUDHL2 cells with reduced expression of
p300ΔC-820 formed approximately 8-fold fewer colonies
in soft agar than control SUDHL2 cells (Figure 4c). Thus,
p300ΔC-820 appears to contribute to in vitro growth
properties of SUDHL2 cells.
p300ΔC-1087 suppresses the expression of
NF-κB-regulated genes encoding A20 and IκBα
Previous results have shown that several REL/NF-κB
target genes are highly expressed in RC-K8 cells [27].
Because REL and p300ΔC-1087 interact in RC-K8 cells
[10], we sought to determine whether knockdown of
p300ΔC-1087 would affect expression of some known
REL-regulated genes in RC-K8 cells. Therefore, qPCR
was performed to compare mRNA levels of seven such
genes (A20, BCL2A1, CCR7, NFKBIA [encoding IκBα],
LTA, TNF, TRAF1) in RC-K8 cells expressing p300 shRNA
to control cells (Figure 4d). First we confirmed by Western
blotting that p300ΔC-1087 expression was reduced in
RC-K8 cells expressing p300 shRNA as compared to
RC-K8 cells expressing a control, non-targeting shRNA
(Figure 4e, top panel). As shown in Figure 4d, expression
of A20, CCR7, NFKBIA, TRAF1, and TNFα mRNAs was
significantly increased (1.1- to 1.5-fold; p < 0.05) in p300
knockdown cells, relative to control RC-K8 cells. Expres-
sion of A1 and LTA were not significantly increased in
RC-K8 cells expressing p300 shRNA.
Extracts from RC-K8 cells with knockdown of p300ΔC-
1087 were next subjected to anti-A20 and anti-IκBα
Western blotting to determine whether the increases in
mRNA seen in these cells resulted in increases in protein
levels. As shown in Figure 4e, A20 and IκBα protein levels
were increased in RC-K8 cells expressing p300 shRNA.
β-tubulin expression was not affected by p300ΔC-1087
knockdown.
We then sought to determine whether the p300ΔC-
1087 protein is located at the A20 promoter in RC-K8
cells. Therefore, we performed a ChIP assay in which
p300ΔC-1087 was immunoprecipitated from RC-K8 cell
nuclei and, after reversing crosslinks, qPCR was per-
formed using primers surrounding the κB sites of the
A20 promoter. As shown in Figure 4f, A20 promotersequences were enriched by approximately four-fold (as
compared to the IgG control) in an anti-p300ΔC-1087
immonoprecipitate from RC-K8 cells.
The expression of p300ΔC-1087 is thus associated
with a reduction in A20 and IκBα expression at both the
mRNA and protein levels. Furthermore, p300ΔC-1087
can be found at the A20 promoter, suggesting that
p300ΔC-1087 has an inhibitory effect on the expression
of A20. This analysis was done on RC-K8 cells, rather
than SUDHL2 cells, because SUDHL2 cells express a
mutant form of A20 protein that is unstable and difficult
to detect [28].Wild-type p300 expression may contribute to overall
histone H3 acetylation in B-cell lymphoma
Because DLBCL cell lines expressing C-terminally trun-
cated, HAT-deficient p300 proteins do not express
detectable amounts of wild-type p300, we next asked
whether there was any reduction in overall histone
acetylation in cell lines lacking wild-type p300 among a
small panel of B-lymphoma cell lines. To do this, we iso-
lated histones from six B-lymphoma cell lines that ex-
press varying levels of wild-type p300, from RC-K8 and
SUDHL2 (which express no detectable wild-type p300
protein), and from Karpas422 cells (which express detect-
able wild-type p300 but no detectable CBP [5] [data not
shown]), and then used a mass spectrometry-based ap-
proach to quantify the degree of acetylation of six lysine
residues on histone H3. The value obtained for each
lysine residue represents the fraction of that residue that
was acetylated relative to the total amount of each resi-
due that was acetylated plus unmodified (Figure 5,
Additional files 2 and 3). Acetylation of H3K9, K56,
and K64 was low and sometimes undetectable in all nine
cell lines. In contrast, acetylation of H3K14, K18, and K23
was within a detectable range and varied among the dif-
ferent cell lines. Cell lines with reduced wild-type p300
or CBP (i.e., RC-K8, SUDHL2, and Karpas422, indi-
cated by red diamonds) had average or below average
levels of H3K14 and H3K18 acetylation (mean and 95%
CIs were H3K14 (0.058 ± 0.091) and H3K18 (0.012 ±
0.014), as compared to the broad range of H3K14 and
H3K18 acetylation values found in cell lines with detectable
levels of full-length p300 and CBP (H3K14, mean 0.252 ±
0.141, H3K18, mean 0.030 ± 0.010) (i.e., Farage, Pfeiffer,
BJAB, Ramos, SUDHL6, and SUDHL8, indicated by blue
circles) (Figure 5, Additional file 2). In contrast, cell
lines lacking detectable wild-type p300 or CBP (i.e.,
SUDHL2, RC-K8, and Karpas422) did not have below
average levels of H3K23 acetylation (mean 0.231 ±
0.039), relative to the broad range of acetylation values
exhibited by cell lines with detectable levels of full-
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Figure 4 Knockdown of p300ΔC reduces proliferation of SUDHL2 cells and increases A20 and IκBα expression in RC-K8 cells. (a) Anti-p300
Western blotting was performed on whole-cell extracts from SUDHL2 cells expressing p300 shRNA or control shRNA. Anti-β-tubulin Western
blotting is a loading control. (b) 105 SUDHL2 cells expressing p300 shRNA or control shRNA were plated in 500 μl RPMI/10% FBS in 16-mm
wells. On each day, three wells of each cell type were counted. (c) Soft agar colony assays were performed using SUDHL2 cells expressing
p300 shRNA or control shRNA. Results are averages of three experiments performed with triplicate plates containing 2000 or 5000 cells. Colony
numbers are normalized to the number of colonies formed by SUDHL2 cells expressing control shRNA (100). Error bars represent standard deviation.
(d) Reverse transcribed total RNA from RC-K8 cells expressing p300 shRNA or a control shRNA was subjected to real-time qPCR using gene-specific
primers. mRNA expression values from RC-K8 cells expressing p300 shRNA were compared to values from RC-K8 cells expressing control shRNA to
determine the fold change in expression. Error bars represent standard error of the mean. Asterisks indicate p-values < 0.05 for the difference in mRNA
levels relative to control cells (=1.0) using a two-tailed t test. (e) Anti-p300, anti-A20, and anti-IκBα Western blotting was performed on whole-cell
extracts from RC-K8 cells expressing p300 shRNA or control shRNA. Anti-β-tubulin Western blotting is a loading control. (f) RC-K8 cells were subjected
to crosslinking with formaldehyde and extracts from isolated nuclei were then immunoprecipitated using normal rabbit IgG or anti-p300 antiserum.
The crosslinks were reversed and DNA in immunoprecipitates was subjected to qPCR using primers spanning the A20 promoter region. Relative A20
promoter PCR product was normalized to the IgG control (1.0). Error bars represent the standard error of the mean.
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In this report, we have characterized molecular proper-
ties of the HAT-deficient p300ΔC-820 protein from the
human DLBCL cell line SUDHL2. This is only the second
truncated p300 mutant that has been functionally charac-
terized in a human DLBCL cell line [10,18]. We show that
p300ΔC-820 is the only form of p300 protein expressed
in SUDHL2 cells and that p300ΔC-820 contributes to
SUDHL2 cell growth, as knockdown of p300ΔC-820
expression compromised the liquid media and soft agar
growth of SUDHL2 cells. Like wild-type p300, p300ΔC-
820 localizes to the nucleus and can interact with NF-κB
family member REL, but p300ΔC-820 has a reduced ability
to enhance REL-dependent transactivation in reporter
assays. As such, p300ΔC mutants have the potential to
attenuate expression of transcription factor-specific target
genes by preventing the interaction of transcription fac-
tors with other functionally intact coactivators. Indeed,
knockdown of p300ΔC-1087 in RC-K8 cells resulted in
increased expression of NF-κB target genes A20, CCR7,
NFKBIA, TRAF1 and TNFα, as well as an increase in
A20 and IκBα protein expression. Finally, the RC-K8and SUDHL2 cell lines, which have reduced expression
of wild-type p300, had generally reduced levels of acetyl-
ation of histone H3 K14 and K18 among a panel of
B-lymphoma cell lines.
Like wild-type p300 and the p300ΔC-1087 protein
from RC-K8 cells, p300ΔC-820 showed a punctate pat-
tern of nuclear staining by immunofluorescence, which
has been associated with sites of active transcription for
wild-type p300 [29]. Using reporter assays, p300ΔC-820
and p300ΔC-1087 are both weak transcriptional coacti-
vators for REL in A293 cells (Figures 2c,d). Because
p300 acts as a transcriptional coactivator through both
HAT-dependent and HAT-independent mechanisms,
the limited coactivator activity retained by these two
C-terminally truncated p300 mutants is likely a function
of protein-protein interactions that result in recruitment
of transcriptional machinery to the transcription start
site (i.e., HAT-independent activities). In some promoter
contexts, such HAT-independent activities may suffice
to maintain normal p300 function. For example, it has
been shown that HAT deletion mutants of p300 can





























Figure 5 Total histone H3 lysine acetylation profile in DLBCL
cell lines. Total histones were extracted from the indicated cell
lines, were trypsinzed, and subjected to mass-spec analysis. For each
H3 lysine residue, the amount of the acetylated lysine residue was
measured relative to total amount of acetylated plus unmodified
residue. Cell lines indicated by red diamonds express undetectable
levels of wild-type p300 (RC-K8, SUDHL2) or wild-type CBP (Karpas422)
by Western blotting. Cell lines indicated by blue circles express
detectable levels of p300 and CBP by Western blotting. A box plot
of the fraction of acetylated lysine residue out of total acetylated
plus unmodified H3 was plotted for each lysine residue. For cell
lines indicated by red diamonds, the mean values and 95% CIs for
H3 lysine acetylation were as follows: H3K14 (0.058 ± 0.091), H3K18
(0.012 ± 0.014), and H3K23 (0.231 ± 0.039). For cell lines indicated
by blue circles, the means and 95% CIs were H3K14 (0.252 ± 0.141),
H3K18 (0.030 ± 0.010), and H3K23 (0.158 ± 0.061).
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coactivators [30]. Thus, it is likely that HAT-deficient
p300 proteins have altered p300 activity in some settings
(e.g., REL-dependent transactivation), but not in others
(e.g., MyoD-dependent transactivation). Therefore, we sug-
gest that cells expressing mutant p300 proteins are distinct
from p300-null cells.
A20 is a tumor suppressor and a target gene of NF-κB,
is biallelically inactivated in approximately 30% of DLBCL,
and is mutated in the SUDHL2 and RC-K8 cell lines
[28,31,32]. Knockdown of p300ΔC-1087 resulted in in-
creased expression of A20 in RC-K8 cells (Figures 4d,e).
That observation and the presence of p300ΔC-1087 at the
A20 promoter (Figure 4f) suggest that p300ΔC-1087 dir-
ectly reduces A20 gene expression in RC-K8 cells, leading
to reduced A20 protein. Reduced A20 protein activity ap-
pears to be essential for RC-K8 and SUDHL2 survival, as
re-expression of wild-type A20 induces apoptosis in both
cell types [28]. Therefore, it appears that A20 activity is re-
duced in SUDHL2 and RC-K8 cells by both mutation [28]
and transcriptional repression mediated by mutant p300.
Knockdown of p300ΔC-1087 in RC-K8 cells also re-
sulted in increased IκBα expression (Figures 4e,f ). We
have previously shown that RC-K8 cells have inactivatingmutations in three of four copies of the NFKBIA gene,
express little wild-type IκBα protein, and consequently
show high levels of both nuclear REL DNA-binding
activity and REL target gene expression [27]. Forced ex-
pression of wild-type IκBα protein slows the growth of
RC-K8 cells, presumably due to inhibition of REL [27].
Taken together, these results suggest that C-terminally
truncated p300 proteins contribute to the oncogenic state
in SUDHL2 and RC-K8 cell lines, at least in part, by redu-
cing expression of both A20 and IκBα, which allows for
tolerable and optimal levels of nuclear NF-κB activity that
promote cell growth. Indeed, both cell lines belong to
the ABC-subtype of DLBCL, which is characterized by
constitutive NF-κB activity and sensitivity to NF-κB in-
hibitors [33]. Overall, we propose that the high levels of
nuclear REL-driven transactivation of target genes that
is unleashed by mutations in the REL/NF-κB inhibitors
A20 and IκBα in RC-K8 and SUDHL2 cells is tempered
by expression of p300ΔC proteins, which act as muted
REL coactivators. The model that moderate, chronic in-
creases in REL-driven target gene expression are optimal
for B-lymphoid cell transformation is reminiscent of the
mutation-driven activation of the lymphoid cell-specific
oncoprotein v-Rel, which is a chronic low level activator
of target gene expression as compared to c-Rel [34].
The CH1 domain of p300 is retained in both p300ΔC-
1087 and p300ΔC-820, and is required for the interaction
of p300 with REL (Figure 3b). Thus, the CH1 domain and
interaction with REL may be important for the growth-
promoting activity of truncated p300 proteins in DLBCL.
In support of this hypothesis, Kimbrel et al. [21] used a
mouse in vivo reconstitution system to show that expres-
sion of a HAT domain mutant of p300 increased the pro-
liferative potential of hematopoietic stem and progenitors
cells, whereas expression of a CH1 domain mutant re-
sulted in severe defects in hematopoiesis.
We have found that DLBCL cell lines with reduced
expression of wild-type p300 generally have low levels of
H3K14 and H3K18 acetylation (Figure 5, Additional files
2 and 3). It has been shown that p300 and CBP are able
to acetylate H3K14 and H3K18 in vitro and that p300 and
CBP are required for H3K18 acetylation in vivo [35,36].
Additionally, hypoacetylation of H3K18 by inhibition of
p300 and CBP stimulates cell cycling in quiescent human
cells and has been associated with recurrence of low-
grade prostate cancer in patient studies [36-38]. Develop-
mental studies in mice have shown that acetylation of
H3K14 is associated with gene activation [39], suggesting
that its reduction in RC-K8 and SUDHL2 cells prevents
expression of target genes specifically related to growth
inhibition and/or apoptosis. Consistent with this hypoth-
esis, H3K14 acetylation at the promoter of the cell cycle
inhibitor p21 is upregulated 10-fold in response to
treatment with the topoisomerase II inhibitor doxorubicin,
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man cancer cell lines [40]. We suggest that expression of
truncated p300 and the associated reduction of wild-type
p300 is one mechanism that can lead to reduced acetyl-
ation of H3K14 and H3K18, which contributes to DLBCL
cell growth. Of note, SUDHL2 and RC-K8 cells are sensi-
tive to apoptosis induced by treatment with two HDAC
inhibitors [41].
Our findings contradict a previously published report
on the lack of full-length p300 protein in the BJAB,
SUDHL8, and Farage DLBCL cell lines [3]. We were able
to show that multiple cell line stocks, including ones
used in the conflicting report, express easily detectable
levels of full-length p300 protein. Thus, we believe that
the lack of full-length p300 protein in these three cell
lines reported in Pasqualucci et al. [3] was due to a tech-
nical error. Northern blotting data reported by Pasqualucci
et al. [3] further support our results, in that the BJAB,
SUDHL8, and Farage cell lines express detectable levels of
full-length p300 mRNA, whereas SUDHL2 cell do not.
Moreover, full-length p300 protein expression in BJAB and
Farage cells has been reported by several others [7,22-25].
Conclusions
Based on our continuing studies, we propose that elimin-
ation of p300 HATactivity and expression of HAT-deletion
p300 mutants both play oncogenic roles in DLBCL.
Specifically, the HAT-independent activities retained in
the truncated p300 proteins contribute to the proliferation
and soft agar growth of certain DLBCL cell lines in vitro.
Future studies will be aimed at identifying other pathways
and genes in DLBCL cells that are affected by the expres-
sion of p300 mutants.
Materials and methods
Plasmids
DNA manipulations were carried out by standard methods
[42]. Complete details of subclones and primers used in
this study are described in supplementary information and
at www.nf-kb.org. GST-p300-CH1 and GST-p300-N340
expression plasmids were kindly provided by Andrew Kung
and have been described previously [14]. All recombinant
DNA and human cell line work was conducted with
BSL-2 level approval of the Boston University Institutional
Biosafety Committee (approval number 11-072).
Cell culture
A293, A293T, BOSC23 human embryonic kidney cells,
DF-1 chicken fibroblasts, and RC-K8 cells were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS) (Biologos,
Montgomery, IL, USA) as described previously [43].
BJAB cells were cultured in DMEM supplemented with
20% FBS. SUDHL2, Ramos, and Farage cells were culturedin RPMI supplemented with 10% FBS. SUDHL8 cells
were cultured in RPMI supplemented with 20% FBS.
The human B-lymphoma cell lines are classified as fol-
lows: DLBCL (BJAB [3,16,44], Farage [2,45], RC-K8 [8],
SUDHL2 [3], SUDHL8 [3,19]), and Burkitt’s lymphoma
(Ramos).
Transfection of A293, A293T, BOSC23, and DF-1 cells
was performed as described previously [18]. For Western
blotting and indirect immunofluorescence, cells were
processed 48 h after addition of the transfection mix.
Design of control and EP300 short hairpin RNAs
(shRNA), generation of virus stocks, and infections were
performed as described previously [18]. Two days after
infection, SUDHL2 and RC-K8 cells were selected with
1 μg/ml puromycin (Sigma, St. Louis, MO, USA), re-
spectively, for 2-4 weeks and maintained in puromycin
throughout all experiments.
Western blotting and indirect immunofluorescence
Whole-cell lysates were prepared in AT buffer containing
protease inhibitors as described previously [46] and were
analyzed by Western blotting according to standard
methods [10]. High molecular weight proteins (full-length
p300 and CBP) were transferred at 260 mA for 2.5 h at
4°C using a modified large-protein transfer buffer (20
mM Tris, 150 mM glycine, 0.05% SDS, 10% methanol) as
described previously [10]. Western blots were quantified
using ImageJ software [47].
The following antisera were used: rabbit anti-p300
(1:200; anti-N-terminal, sc-584, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), rabbit anti-REL (1:200; obtained
from Nancy Rice [43]), mouse anti-CBP (1:200; sc-7300,
Santa Cruz Biotechnology), mouse anti-A20 (1:200, 550859,
BD Pharmingen, Franklin Lakes, NJ, USA), mouse anti-
IκBα (1:1000, 4814, Cell Signaling Technology), and rabbit
anti-β-tubulin (1:500; sc-9104, Santa Cruz Biotechnology).
Indirect immunofluorescence was performed as de-
scribed previously [18,43] using anti-p300 (1:50; sc-584,
Santa Cruz Biotechnology) primary antibody and fluores-
cein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG
(1:80; Sigma) secondary antibody. Nuclei were also
stained with 4’,6-diamidino-2-phenylindole (DAPI). Cells
were visualized using a fluorescent microscope (Olympus
FLUOVIEW Laser Scanner Microscope BX 50, Center
Valley, PA, USA).
Co-immunoprecipitation
For co-immunoprecipitation of overexpressed proteins,
A293 cells in 100-mm dishes were co-transfected with
10 μg pcDNA-Flag-REL and 10 μg pCMVβ-p300ΔC-
820. Two days later, nuclear extracts were prepared using
a Nuclear Complex Co-IP Kit (cat no. 54001, Active Motif,
Carlsbad, CA, USA) according to the manufacturer’s in-
structions. Nuclear extracts containing 300 μg of protein
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immune serum for 3 h at 4°C. 100 μl of a 50% slurry
of Protein A Sepharose CL-4B (GE Healthcare Life
Sciences, Pittsburgh, PA, USA) was added and the sam-
ple was incubated for an additional 1 h at 4°C. The
beads were then washed in PBS and proteins were eluted
by heating at 95°C in SDS sample buffer. Proteins were
electrophoresed on a 7.5% SDS-polyacrylamide gel and
transferred to a nitrocellulose membrane as described
above. One percent of the amount of nuclear extract used
for one immunoprecipitation (3 μg) was included on the
gel as an input lane. The membranes were then subjected
to anti-REL Western blotting.
Co-immunoprecipitation of endogenous REL and p300ΔC-
820 in SUDHL2 cells was performed using the Nuclear
Complex Co-IP Kit as described by the manufacturer
(cat. no. 54001, Active Motif). Three micrograms of nor-
mal rabbit IgG (sc-2027, Santa Cruz Biotechnology) or
anti-p300 antiserum (sc-584, Santa Cruz Biotechnology)
was incubated with 250 μg of nuclear extract in IP Low
Buffer (Active Motif ) for 3 h at 4°C. 50 μl of a 50%
slurry of Protein A Sepharose CL-4B (GE Healthcare
Life Sciences) was added, and samples were incubated
for an additional 3 h. Beads were then washed with IP
Low Buffer and proteins were eluted by heating at 95°C
in SDS sample buffer. Proteins were electrophoresed on
a 6% SDS-polyacrylamide gel and transferred to a nitro-
cellulose membrane as described above. Ten percent of
the amount of nuclear extract used for one immunopre-
cipitation (25 μg) was included on the gel as an input lane.
The membranes were then subjected to anti-REL or anti-
p300 Western blotting.
GST pulldown assays
GST pulldown assays followed by Western blotting were
performed as described previously [10]. One percent of
the amount of extract used for each pulldown (30 μg)
was included on the gel as an input lane. The membrane
was then subjected to anti-p300 or anti-REL Western
blotting.
Luciferase reporter assays
Luciferase reporter assays were performed using the
Luciferase Assay System (Promega, Madison, WI, USA)
as described previously [18]. A293 cells in 35-mm plates
were transfected with 0.5 μg of reporter plasmid pGL2-
3×-κB-luciferase and 0.5 μg of normalization plasmid
pRSV-βgal. Cells were co-transfected with 0.5 μg of
pcDNA-REL or pcDNA3.1 vector alone, along with
0.5 μg of pCMVβ-p300, pCMVβ-p300ΔC, or vector
alone. In titration experiments (Figure 2d), cells were
transfected with 0.5 μg of pcDNA-REL, and increasing
amounts of pCMVβ-p300, pCMVβ-p300ΔC-1087, or
pCMVβ-p300ΔC-820. Increasing amounts of each p300plasmid were titrated in until luciferase activity reached
a plateau. For all luciferase reporter assay experiments,
total DNA per transfection was kept constant by including
varying amounts of pcDNA3.1 vector. Luciferase and
β-galactosidase activities were determined, and values
were normalized to the relevant vector control (1.0).
Statistical analyses were performed using a paired one-
tailed t-test and p < 0.05 was considered significant.
Cell proliferation and soft agar assays
Cell proliferation and soft agar colony assays were per-
formed as described previously [18,48]. Equal numbers
(2000 and 5000) of SUDHL2 cells expressing the indi-
cated shRNA were placed in soft agar containing RPMI
with 20% FBS and 0.3% Bacto Agar (Difco, Franklin
Lakes, NJ, USA), and plates were incubated at 37°C in a
humid incubator with 5% CO2. Macroscopic colonies
were counted 14 days after plating.
Chromatin immunoprecipitation assays and qPCR
For ChIP assays, approximately 108 RC-K8 cells were fixed
with 3% formaldehyde for 20 min at room temperature.
Cells were then rinsed three times with ice-cold PBS and
nuclear lysate was prepared as described previously [49].
Samples containing 350 μg of protein were then incubated
at 4°C overnight with either rabbit anti-p300 antiserum or
pre-immune serum. The next day, 50 μl of a 50% slurry of
protein A beads was added and the reaction was incubated
for 3 h at 4°C. Beads were washed with RIPA buffer (50
mM Tris-HCl pH 7.2, 150 mM NaCl, 1% deoxycholic
acid, 1% Triton X-100, 0.1% SDS) and then TE supple-
mented with 50 mM NaCl. Beads were eluted in TE
with 2% SDS for 15 min at 65°C. Crosslink reversal and
DNA purification were performed as described previously
[49]. Purified DNA was then subjected to qPCR using
primers to amplify the TNFAIP3 (A20) promoter. PCRs
were performed in the ABI Prism 7900HT Sequence Detec-
tion System (Applied Biosystems, Foster City, CA, USA)
using 40 cycles of 94°C for 15 s and 60°C for 1 min. The
primers used were 5’-CAGCCCGACCCAGAGAGTCAC
and 5’-TTCGTGGCGGGCCAAG [50]. Cycle threshold (Ct)
values for p300 were normalized to the pre-immune serum
control values (1.0). Error bars represent standard error.
PCR and real-time quantitative PCR
Two hundred ng of genomic DNA from SUDHL2 cells
was subjected to PCR using forward and reverse primers
specific for sequences surrounding exon 14 of EP300.
The primers used were 5’- AGCATAGGCAGGCCCTAGA
and 5’- TATGCTTGGGGGAGTATGGT. Sequencing of
the amplified fragment was performed by Eurofins MWG
Operon (Huntsville, AL, USA).
For qPCR of mRNA, total RNA was first isolated from
RC-K8 cells using TRIzol Reagent (Invitrogen, Grand
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col. The mRNA was reverse transcribed into cDNA using
M-MLV reverse transcriptase (Promega) and random
primers (Promega). One thirtieth of the synthesized cDNA
was combined with gene-specific primers and Power
SYBR Green PCR Master Mix (Applied Biosystems). PCRs
were performed as described above. Ct values were ob-
tained for each sample and normalized to Ct values for
GAPDH cDNA amplification (ΔCt) and then to Ct values
from control shRNA-expressing RC-K8 cells (ΔΔCt) using
methods described previously [51]. The fold change in
mRNA was normalized to the fold change in GAPDH
mRNA expression (1.0) between p300 and control knock-
down RC-K8 cells. Primers used were A20: 5’- CGCTCA
AGGAAACAGACACA and 5’- CTTCAGGGTCACCA
AGGGTA; CCR7: 5’-TGAGGTCACGGACGATTACAT
and 5’- GTAGGCCCACGAAACAAATGAT; NFKBIA:
5’- CTCCGAGACTTTCGAGGAAATAC and 5’- GCCATT
GTAGTTGGTAGCCTTCA; TRAF1: 5’- TCCTGTGGAA
GATCACCAATGT and 5’- GCAGGCACAACTTGTAG
CC; TNF: 5’- GAGGCCAAGCCCTGGTATG and 5’- CG
GGCCGATTGATCTCAGC; LTA: 5’- CATCTACTTCGT
CTACTCCCAGG and 5’-CCCCGTGGTACATCGAGTG;
A1: 5’- TACAGGCTGGCTCAGGACTAT and 5’- CGCA
ACATTTTGTAGCACTCTG; GAPDH: 5’- TGGTATCG
TGGAAGGACTCATGAC and 5’- ATGCCAGTGAGCT
TCCCGTTCAGC.
Statistical analyses were performed using a paired two-
tailed t-test, and p < 0.05 was considered significant.
Quantification of histone acetylation via mass
spectrometry
Cell lines were maintained in healthy conditions for sev-
eral passages before histones were purified using the
Active Motif Histone Purification Kit (cat no. 40025)
according to the manufacturer’s instructions. Concentra-
tions were determined using Nanodrop, 5 μg of each
sample was chemically propionylated using 1.5 μl pro-
pionic anhydride, and ammonium hydroxide was used to
quickly adjust the pH to approximately 8.0 [52]. Samples
were then incubated at 51°C for 1 h followed by trypsin
digestion overnight at 37°C. The fraction of acetylated to
unmodified at a given histone H3 site was performed as
described previously [53]. Means and 95% confidence
intervals of acetylation values for different cell lines
were calculated.
Additional files
Additional file 1: SUDHL2 cells do not have a wild-type EP300
sequence at codon 821. Genomic DNA corresponding to exon 14 of
EP300 was sequenced in SUDHL2 cells. Sequencing was performed in the
forward (top strand) and reverse (bottom strand) direction. Chromatograms
and corresponding nucleotides are shown in the forward (top strand) andreverse (bottom strand) direction. The reported C2856T nonsense mutation
at codon 821 [3] is highlighted.
Additional file 2: Relative histone H3 acetylation profile in DLBCL
cell lines. Total histones were extracted from the indicated cell lines. For
each H3 lysine residue, the amount of the acetylated lysine residue is
reported relative to total amount of acetylated plus unmodified residue.
To generate the relative fraction of acetylated H3, a single common
maximum value and single common minimum value were applied to all
lysine residues analyzed, and absolute values (Figure 5) within each
residue were distributed proportionally across this normalized range. The
relative fraction of acetylated H3 for all cell lines is shown as a box plot
for each lysine residue. Cell lines indicated by red diamonds express
undetectable levels of wild-type p300 (RC-K8, SUDHL2) or wild-type CBP
(Karpas422) by Western blotting. Cell lines indicated by blue circles
express detectable levels of full-length p300 and CBP by Western blotting.
Additional file 3: Fraction of acetylated lysine residue relative to
total acetylated plus unmodified residue in Histone H3. Fraction of
acetylated lysine residue as determined by mass spectrometry for
B-lymphoma cell lines. Values are plotted in Figure 5.
Abbreviations
aa: Amino acid (s); bp: Base pair; CH1: Cysteine/histidine-rich 1;
CI: Confidence interval; DLBCL: Diffuse large B-cell lymphoma;
DMEM: Dulbecco’s modified Eagle’s medium; FBS: Fetal bovine serum;
GST: Glutathione S-transferase; HAT: Histone acetyltransferase;
PCR: Polymerase chain reaction; PEI: Polyethylenimine; shRNA: Short hairpin
RNA; TAD: Transactivation domain.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LH performed all experiments except for full-length p300 detection in multiple
DLBCL isolates (JL-P) and mass-spectrometry analysis of histone H3 acetylation
(RAH, AJA). LH and TDG designed the studies and analyzed and interpreted
the data. LH and TDG wrote the manuscript. All authors read and approved
the final manuscript.
Acknowledgements
We thank Drs. Laura Pasqualucci, Leonardo Cerchietti, Ricardo Dalla-Favera,
David Thorley-Lawson, Gerald Denis, and Alan Yeo for human B-lymphoma
cell lines and helpful discussions. We thank Dr. Andrew L. Kung for GST-
tagged p300 expression plasmids and helpful discussions. This work was sup-
ported by NIH ARRA supplement CA047763-21S3 (to TDG). LH was supported
by NHLBI Hematology training grant T32 HL007501 and NSF GK-12 grant DGE-
0947950. JLP was supported by NSF-REU grant DBI-085171. RH and AJA were
supported by the WW Smith Trust and by a grant from the Pennsylvania
Department of Health. The Pennsylvania Department of Health specifically
disclaims
responsibility for any analysis, interpretations or conclusions.
Author details
1Department of Biology, Boston University, 5 Cummington Mall, Boston,
MA 02215, USA. 2Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Received: 14 June 2013 Accepted: 5 February 2014
Published: 15 February 2014
References
1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS:
Lymphoma incidence patterns by WHO subtype in the United States,
1992-2001. Blood 2006, 107:265–276.
2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC,
Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L,
Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD,
Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D,
Brown PO, et al: Distinct types of diffuse large B-cell lymphoma identified
by gene expression profiling. Nature 2000, 403:503–511.
3. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V,
Kasper LH, Lerach S, Tang H, Ma J, Rossi D, Chadburn A, Murty VV, Mullighan CG,
Haery et al. Molecular Cancer 2014, 13:29 Page 12 of 13
http://www.molecular-cancer.com/content/13/1/29Gaidano G, Rabadan R, Brindle PK, Dalla-Favera R: Inactivating mutations of
acetyltransferase genes in B-cell lymphoma. Nature 2011, 471:189–195.
4. Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, Wells VA,
Grunn A, Messina M, Elliot O, Chan J, Bhagat G, Chadburn A, Gaidano G,
Mullighan CG, Rabadan R, Dalla-Favera R: Analysis of the coding genome
of diffuse large B-cell lymphoma. Nat Genet 2011, 43:830–837.
5. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD,
Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M,
Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M,
Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M,
Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, et al:
Frequent mutation of histone-modifying genes in non-Hodgkin
lymphoma. Nature 2011, 476:298–303.
6. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C,
Cruz-Gordillo P, Knoechel B, Asmann YW, Slager SL, Novak AJ, Dogan A,
Ansell SM, Link BK, Zou L, Gould J, Saksena G, Stransky N, Rangel-Escareno C,
Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Hernandez-Lemus
E, Schwarz-Cruz Y, Celis A, Imaz-Rosshandler I, Ojesina AI, Jung J, Pedamallu CS,
Lander ES, Habermann TM, et al: Discovery and prioritization of somatic
mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome
sequencing. Proc Natl Acad Sci U S A 2012, 109:3879–3884.
7. Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M,
Mendez L, Shaknovich R, Cole PA, Bhalla K, Gascoyne RD, Marra M, Chiosis G,
Melnick A: BCL6 repression of EP300 in human diffuse large B cell
lymphoma cells provides a basis for rational combinatorial therapy.
J Clin Invest 2010, 120:4569–4582.
8. Giordano A, Avantaggiati ML: p300 and CBP: partners for life and death.
J Cell Physiol 1999, 181:218–230.
9. Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T: CREB-binding
protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci
U S A 1997, 94:2927–2932.
10. Garbati MR, Alço G, Gilmore TD: Histone acetyltransferase p300 is a
coactivator for transcription factor REL and is C-terminally truncated in
the human diffuse large B-cell lymphoma cell line RC-K8. Cancer Lett
2010, 291:237–245.
11. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K:
Recruitment of p300/CBP in p53-dependent signal pathways. Cell 1997,
89:1175–1184.
12. Lee CW, Arai M, Martinez-Yamout MA, Dyson HJ, Wright PE: Mapping the
interactions of the p53 transactivation domain with the KIX domain of
CBP. Biochemistry 2009, 48:2115–2124.
13. Sartorelli V, Huang J, Hamamori Y, Kedes L: Molecular mechanisms of
myogenic coactivation by p300: direct interaction with the activation
domain of MyoD and with the MADS box of MEF2C. Mol Cell Biol 1997,
17:1010–1026.
14. Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM: Suppression of
tumor growth through disruption of hypoxia-inducible transcription.
Nat Med 2000, 6:1335–1340.
15. Pao GM, Janknecht R, Ruffner H, Hunter T, Verma IM: CBP/p300 interact
with and function as transcriptional coactivators of BRCA1. Proc Natl
Acad Sci U S A 2000, 97:1020–1025.
16. Yang C, Shapiro LH, Rivera M, Kumar A, Brindle PK: A role for CREB binding
protein and p300 transcriptional coactivators in Ets-1 transactivation
functions. Mol Cell Biol 1998, 18:2218–2229.
17. Abraham SE, Lobo S, Yaciuk P, Wang HG, Moran E: p300, and p300-associated
proteins, are components of TATA-binding protein (TBP) complexes.
Oncogene 1993, 8:1639–1647.
18. Garbati MR, Thompson RC, Haery L, Gilmore TD: A rearranged EP300 gene
in the human B-cell lymphoma cell line RC-K8 encodes a disabled
transcriptional co-activator that contributes to cell growth and
oncogenicity. Cancer Lett 2011, 302:76–83.
19. Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF, Daigo Y,
Russell P, Wilson A, Sowter HM, Delhanty JD, Ponder BA, Kouzarides T,
Caldas C: Mutations truncating the EP300 acetylase in human cancers.
Nat Genet 2000, 24:300–303.
20. Ionov Y, Matsui S, Cowell JK: A role for p300/CREB binding protein genes
in promoting cancer progression in colon cancer cell lines with
microsatellite instability. Proc Natl Acad Sci U S A 2004, 101:1273–1278.
21. Kimbrel EA, Lemieux ME, Xia X, Davis TN, Rebel VI, Kung AL: Systematic
in vivo structure-function analysis of p300 in hematopoiesis. Blood 2009,
114:4804–4812.22. Eckner R, Yao TP, Oldread E, Livingston DM: Interaction and functional
collaboration of p300/CBP and bHLH proteins in muscle and B-cell
differentiation. Genes Dev 1996, 10:2478–2490.
23. Li M, Damania B, Alvarez X, Ogryzko V, Ozato K, Jung JU: Inhibition of p300
histone acetyltransferase by viral interferon regulatory factor.
Mol Cell Biol 2000, 20:8254–8263.
24. Wang L, Grossman SR, Kieff E: Epstein-Barr virus nuclear protein 2 interacts
with p300, CBP, and PCAF histone acetyltransferases in activation of the
LMP1 promoter. Proc Natl Acad Sci U S A 2000, 97:430–435.
25. Cotter MA 2nd, Robertson ES: Modulation of histone acetyltransferase
activity through interaction of Epstein-Barr nuclear antigen 3C with
prothymosin alpha. Mol Cell Biol 2000, 20:5722–5735.
26. Sankar N, Baluchamy S, Kadeppagari RK, Singhal G, Weitzman S,
Thimmapaya B: p300 provides a corepressor function by cooperating
with YY1 and HDAC3 to repress c-Myc. Oncogene 2008, 27:5717–5728.
27. Kalaitzidis D, Davis RE, Rosenwald A, Staudt LM, Gilmore TD: The human
B-cell lymphoma cell line RC-K8 has multiple genetic alterations that
dysregulate the Rel/NF-κB signal transduction pathway. Oncogene 2002,
21:8759–8768.
28. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q,
Bertoni F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A,
Dalla-Favera R, Pasqualucci L: Mutations of multiple genes cause
deregulation of NF-κB in diffuse large B-cell lymphoma. Nature 2009,
459:717–721.
29. von Mikecz A, Zhang S, Montminy M, Tan EM, Hemmerich P: CREB-binding
protein (CBP)/p300 and RNA polymerase II colocalize in transcriptionally
active domains in the nucleus. J Cell Biol 2000, 150:265–273.
30. Puri PL, Sartorelli V, Yang XJ, Hamamori Y, Ogryzko VV, Howard BH, Kedes L,
Wang JY, Graessmann A, Nakatani Y, Levrero M: Differential roles of
p300 and PCAF acetyltransferases in muscle differentiation.
Mol Cell 1997, 1:35–45.
31. Wertz IE, O’Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C,
Baker R, Boone DL, Ma A, Koonin EV, Dixit VM: De-ubiquitination and
ubiquitin ligase domains of A20 downregulate NF-κB signalling.
Nature 2004, 430:694–699.
32. Krikos A, Laherty CD, Dixit VM: Transcriptional activation of the tumor
necrosis factor α-inducible zinc finger protein, A20, is mediated by κB
elements. J Biol Chem 1992, 267:17971–17976.
33. Lim KH, Yang Y, Staudt LM: Pathogenetic importance and therapeutic
implications of NF-κB in lymphoid malignancies. Immunol Rev 2012,
246:359–378.
34. Gilmore TD: Multiple mutations contribute to the oncogenicity of the
retroviral oncoprotein v-Rel. Oncogene 1999, 18:6925–6937.
35. Luebben WR, Sharma N, Nyborg JK: Nucleosome eviction and activated
transcription require p300 acetylation of histone H3 lysine 14. Proc Natl
Acad Sci U S A 2010, 107:19254–19259.
36. Horwitz GA, Zhang K, McBrian MA, Grunstein M, Kurdistani SK, Berk AJ:
Adenovirus small e1a alters global patterns of histone modification.
Science 2008, 321:1084–1085.
37. Ferrari R, Pellegrini M, Horwitz GA, Xie W, Berk AJ, Kurdistani SK: Epigenetic
reprogramming by adenovirus e1a. Science 2008, 321:1086–1088.
38. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK: Global
histone modification patterns predict risk of prostate cancer recurrence.
Nature 2005, 435:1262–1266.
39. Kueh AJ, Dixon MP, Voss AK, Thomas T: HBO1 is required for H3K14
acetylation and normal transcriptional activity during embryonic
development. Mol Cell Biol 2011, 31:845–860.
40. Love IM, Sekaric P, Shi D, Grossman SR, Androphy EJ: The histone
acetyltransferase PCAF regulates p21 transcription through stress-induced
acetylation of histone H3. Cell Cycle 2012, 11:2458–2466.
41. Thompson RC, Vardinogiannis I, Gilmore TD: The sensitivity of diffuse large
B-cell lymphoma cell lines to histone deacetylase inhibitor-induced
apoptosis is modulated by BCL-2 family protein activity. PLoS One 2013,
8:e62822.
42. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory
Manual. 2nd edition. Cold Spring Harbor, NY: Cold Spring Harbor
Laboratory Press; 1989.
43. Starczynowski DT, Reynolds JG, Gilmore TD: Mutations of tumor necrosis
factor α-responsive serine residues within the C-terminal transactivation
domain of human transcription factor REL enhance its in vitro transforming
ability. Oncogene 2005, 24:7355–7368.
Haery et al. Molecular Cancer 2014, 13:29 Page 13 of 13
http://www.molecular-cancer.com/content/13/1/2944. Sun CC, Thorley-Lawson DA: Plasma cell-specific transcription factor XBP-1 s
binds to and transactivates the Epstein-Barr virus BZLF1 promoter. J Virol
2007, 81:13566–13577.
45. Longe HO, Romesser PB, Rankin AM, Faller DV, Eller MS, Gilchrest BA, Denis GV:
Telomere homolog oligonucleotides induce apoptosis in malignant but not
in normal lymphoid cells: mechanism and therapeutic potential. Int J Cancer
2009, 124:473–482.
46. Liang M-C, Bardhan S, Porco JA Jr, Gilmore TD: The synthetic epoxyquinoids
jesterone dimer and epoxyquinone A monomer induce apoptosis and
inhibit REL (human c-Rel) DNA binding in an IkappaBalpha-deficient
diffuse large B-cell lymphoma cell line. Cancer Lett 2006, 241:69–78.
47. ImageJ. [imagej.nih.gov/ij/]
48. Chin M, Herscovitch M, Zhang N, Waxman DJ, Gilmore TD: Overexpression
of an activated REL mutant enhances the transformed state of the
human B-lymphoma BJAB cell line and alters its gene expression profile.
Oncogene 2009, 28:2100–2111.
49. Lee TI, Johnstone SE, Young RA: Chromatin immunoprecipitation and
microarray-based analysis of protein location. Nat Protoc 2006, 1:729–748.
50. Amir-Zilberstein L, Ainbinder E, Toube L, Yamaguchi Y, Handa H, Dikstein R:
Differential regulation of NF-κB by elongation factors is determined by
core promoter type. Mol Cell Biol 2007, 27:5246–5259.
51. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C (T)) Method.
Methods 2001, 25:402–408.
52. Garcia BA, Mollah S, Ueberheide BM, Busby SA, Muratore TL, Shabanowitz J,
Hunt DF: Chemical derivatization of histones for facilitated analysis by
mass spectrometry. Nat Protoc 2007, 2:933–938.
53. Kuo YM, Andrews AJ: Quantitating the specificity and selectivity of
Gcn5-mediated acetylation of histone H3. PLoS One 2013, 8:e54896.
doi:10.1186/1476-4598-13-29
Cite this article as: Haery et al.: Histone acetyltransferase-deficient p300
mutants in diffuse large B cell lymphoma have altered transcriptional
regulatory activities and are required for optimal cell growth. Molecular
Cancer 2014 13:29.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
